For flea allergy dermatitis (FAD), a common allergic skin disease of dogs, flea control is the most important component of treatment. In this open-label, small-scale study, 20 dogs with signs of FAD and proven hypersensitivity (positive intradermal flea antigen test and/or positive serology flea antigen-specific IgE antibody test) were enrolled. Dogs were treated once with an oral flea control product (fluralaner; Bravecto, bravecto.com). Dogs were evaluated at 4-week intervals for 12 weeks. Clinical signs were monitored via Canine Atopic Dermatitis Extent and Severity Index (CADESI) scoring and owner-marked Pruritus Visual Analog Scale (PVAS).
At 4 weeks, only 1/20 dogs was found to have fleas (n = 1 flea) and clinical signs of FAD had resolved in all dogs. At 8 weeks, 2/20 dogs had mild signs of FAD, but by 12 weeks all clinical signs had resolved. Flea counts were negative for all dogs at 8 and 12 weeks. CADESI and PVAS scores decreased throughout the study period, with the most significant decreases occurring in the initial 4 weeks posttreatment. No treatment-related adverse events were reported. The authors concluded that a single dose of fluralaner can control fleas and may improve signs of FAD in dogs for 12 weeks. Funding for study provided by MSD Animal Health.